Biologics, a cancer management company that offers clinical trial materials management as part of its services, has been selected by the National Marrow Donor Program (NMDP) to manage a phase III clinical trial.
Biologics’ Oncology Clinical Trial Services division will provide pharmacy management services for the nonprofit organization’s clinical trial of filgrastim (Neupogen)-simulated peripheral blood stem cells (PBSC) in hematopoietic cell transplants involving unrelated donors. PBSC, according to the NMDP, is used more often than marrow for adult patients in need of allogeneic and autologous transplants.
Biologics will manage inventory and coordinate the delivery of 200 shipments of Neupogen a month to 50 NMDP donor sites as part of the trial. This process is particularly time-sensitive because the drug must be shipped overnight in temperature-controlled packaging to successfully support the transplant schedule. Although Biologics has just recently become involved in this clinical trial, the trial has been ongoing since 1997.